No Myth: CEO of ADC upstart calls it quits; Bristol Myers vet Jon Wigginton scales new heights at Bright Peak
→ When Mythic Therapeutics CEO Alex Nichols spoke to Endpoints News last December about the biotech’s $103 million Series B, he and fellow co-founder Brian Fiske emphasized safety, saying that they’re “really working on trying to overcome what has been one of the most historically challenging obstacles to realizing the full potential of ADCs.” But Mythic will have to look for someone else to take up that mantle.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.